Evidence map›Paper›PMID 42663800›Full record

ArticlePurinergic signalling2026

Effects on mouse melanoma and immune cells of P2X7 receptor positive allosterism by clemastine.

Maria Luiza Thorstenberg, Simonetta Falzoni, Rocio Edith Garcia-Jacobo, Leticia Scussel Bergamin, Mario Tarantini, Giulia Conversano, Anna Pegoraro, Francesco Di Virgilio, Elena Adinolfi, Anna Lisa Giuliani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria Luiza ThorstenbergDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Simonetta FalzoniDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Rocio Edith Garcia-JacoboDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Leticia Scussel BergaminDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Mario TarantiniDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Giulia ConversanoDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Anna PegoraroDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Francesco Di VirgilioDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Elena AdinolfiDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy.
Anna Lisa GiulianiDepartment of Medical Sciences, University of Ferrara, Via Luigi Borsari, 46, Ferrara, 44121, Italy. a.giuliani@unife.it.

Funding

COST (European Cooperation in Science and Technology) PRESTO COST Action CA21130Italian Association for Cancer Research (AIRC) IG 22883Ministry of Education of Italy PRIN No. 20178YTNWCMinistry of Education of Italy PRIN No. 2022943TH9TRANSCAN3 00094 PUR-THER TRANSCAN-3 JTC2021 Project
6 · The paper itself

Abstract

Clemastine (CLE), an H1R antagonist widely used for the treatment of allergic rhinitis, has recently been investigated for its positive modulatory effects on P2X7, a receptor for extracellular ATP (eATP) involved in the regulation of inflammation, immune responses, and the composition of the tumor microenvironment (TME). Here, we further examined the effects of CLE on P2X7-mediated responses to clarify the pharmacological significance of P2X7 potentiation. First, in murine and human cells expressing (B16F10 WT and HEK293-hP2X7) or lacking (B16F10 P2X7

Indexed as

ClemastineMelanoma, ExperimentalPurinergic P2X Receptor AgonistsReceptors, Purinergic P2X7Adenosine TriphosphateAnimalsHEK293 CellsHumansMiceMice, Inbred C57BLAdenosine TriphosphateClemastinePurinergic P2X Receptor AgonistsReceptors, Purinergic P2X7B16F10 melanoma cellsClemastineIL-1βMacrophagesP2X7 receptor

Identifiers

PMID42663800
PMCPMC13525124

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.